The Latest Cardiac and Vascular News
Paul Verrastro Named CMO and Thomas Hengsteler Named VP of European Sales and Marketing MINNEAPOLIS, Jan. 05, 2021 (GLOBE NEWSWIRE) — CVRx®, developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure (HF), announced that it is expanding its senior leadership team by adding two medical […]
Incremental Reimbursement in Outpatient Setting Will Expand Availability of the Breakthrough BAROSTIM Therapy Heart Failure Treatment MINNEAPOLIS, Dec. 03, 2020 (GLOBE NEWSWIRE) — CVRx®, developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure (HF), announced that the Centers for Medicare and Medicaid Services (CMS) granted […]
MINNEAPOLIS, Nov. 18, 2020 (GLOBE NEWSWIRE) — CVRx, Inc., developer of FDA-approved Barostim Therapy to treat chronic heart failure (HF), announced a CFO transition as part of the company’s long-term growth plan. Jared Oasheim, who joined CVRx in 2015, was promoted from Vice President of Finance to Chief Financial Officer (CFO). He […]
CVRx Enrolls the First Patient in a Post Market Heart Failure Registry MINNEAPOLIS, July 21, 2020 /PRNewswire/ — CVRx, Inc., a private medical device company, announced that the BeAT-HF phase III randomized clinical trial has completed enrollment in the post-market phase. CVRx has also enrolled the first patient in a heart failure (“HF”) […]
Offering Will Support US Commercialization of BAROSTIM NEOTM MINNEAPOLIS, July 7, 2020 /PRNewswire/ — CVRx, Inc., a private medical device company with a novel technology that treats patients suffering from chronic heart failure (“HF”) and resistant hypertension, announced today that it raised $50 million to close its latest round of equity financing. Proceeds from the […]
BAROSTIM NEO™ is the World’s First Heart Failure Neuromodulation Device MINNEAPOLIS, June 30, 2020 /PRNewswire/ — CVRx, Inc., a private medical device company, announced today that its BeAT-HF phase III randomized clinical trial results were published in the Journal of the American College of Cardiology (“JACC”). Results from the trial were used […]
BeAT-HF Trial Results Presented as Late-Breaking Clinical Science at ESC Heart Failure 2020 Meeting MINNEAPOLIS, June 23, 2020 /PRNewswire/ — CVRx, Inc., a private medical device company, announced new BeAT-HF trial results from late-breaking clinical science presented virtually at the European Society of Cardiology Heart Failure 2020 Scientific Sessions. The BAROSTIM NEO […]
